Stockreport

Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF The company's proprietary base-editing technology potentially enables the development of a differentiated class of precision genetic medicines that target a single base [Read more]